OMCAZIO approved for administration without regard to food, removing strict fasting requirements for cabozantinib patients SAN JOSE, CA AND TAIPEI, TW / September 11, 2026 / Handa Pharmaceuticals, Inc. (“Handa” or the “Company”) (TSE:6620) announced that the U.S. Food and Drug Administration (“FDA”) has granted final approval to OMCAZIO™ (cabozantinib) capsules, the laurylsulfate salt formulation...Read More

Handa Oncology Receives FDA Tentative Approval for OMCAZIO™ (cabozantinib) Capsules A novel 505(b)(2) alternate-salt formulation of cabozantinib designed to improve absorption, with no clinically significant food effect TAIPEI, TW / Handa Pharmaceuticals, Inc. (“Handa”) (TSE:6620) announced that the U.S. Food and Drug Administration (“FDA”) has granted tentative approval to OMCAZIO™ (cabozantinib) capsules, a novel alternate-salt...Read More

PHYRAGO™ Represents the First and Only Improved Version of SPRYCEL® That Can Be Safely Co-administered With Gastric Acid-Reducing Agents TAIPEI, TAIWAN / ACCESSWIRE / January 15, 2025 / Handa Pharmaceuticals, Inc. (“Handa”) (6620.TWO) announced that its U.S. subsidiary, Handa Therapeutics, LLC (the “Company”), has acquired PHYRAGO™ (dasatinib) tablets, a U.S. Food and Drug Administration (“FDA”) approved chronic...Read More